<?xml version="1.1" encoding="UTF-8" standalone="yes"?><xml><head><creation_date>D:20210304145400Z</creation_date><modification_date>D:20210304145400Z</modification_date><initial_authorization>False</initial_authorization><pdf_file>EU-1-18-1299_h_dec_4.pdf</pdf_file></head><body><section><header>enen</header><p>european commission
 brussels, 10.3.2021c(2021)1726 (final)</p></section><section><header>commission implementing decisionof 10.3.2021
 correcting decision c(2020)8457 final of 25.11.2020 amending the marketing authorisation 
 granted by decision c(2018)5718 final for “yescarta - axicabtagene ciloleucel”, an orphan 
 medicinal product for human use</header><p>(text with eea relevance) (only the dutch text is aut hentic)</p></section><section><header>en</header><p>1</p></section><section><header>en</header></section><section><header>commission implementing decisionof 10.3.2021
 correcting decision c(2020)8457 final of 25.11.2020 amending the marketing authorisation 
 granted by decision c(2018)5718 final for “yescarta - axicabtagene ciloleucel”, an orphan 
 medicinal product for human use</header><p>(text with eea relevance)(only the dutch text is aut hentic)
 the european commission,
 having regard to the treaty on the functioning of the european union,
 having regard to regulation (ec) no 726/2004 of the european parliament and of the council of 
 31 march 2004 laying down community procedures for the authorisation and supervision of 
 medicinal products for human and veterinary use and establishing a european medicines agency
 1,having regard to commission regulation (ec) no 1234/2008 of 24 november 2008 concerning 
 the examination of variations to the terms of marketing authorisations for medicinal products for 
 human use and veterinary medicinal products
 2, and in particular article 17(2) thereof,having regard to the changes to the terms of the decision granting the marketing authorisation 
 requested by kite pharma eu b.v. in accordance with regulation (ec) no 1234/2008,
 having regard to the opinion of the european medicines agency, formulated on 28 may 2020 by 
 the committee for medicinal products for human use,
 whereas:
 (1)
 the commission has been made aware that the product information (pi) of decision 
 c(2020)8457 final</p><p>of 25.11.2020 requires linguistic amendments.
 (2)
 this decision rectifies decision c(2020)8457 final by correcting the relevant annexes i, 
 ii and iii accordingly. it should apply retroactively from the date of notification of that 
 decision.
 has adopted this decision:
 article 1decision c(2020)8457 final is corrected as follows:1oj l 136, 30.4.2004, p. 1.2oj l 334, 12.12.2008, p. 7.</p></section><section><header>en</header><p>2</p></section><section><header>en</header><p>annexes i, ii and iii shall be replaced by the text set out in annexes i, ii and iii to this decision.article 2this decision applies from 26 november 2020. article 3this decision is addressed to kite pharma eu b.v., tufsteen 1, 2132 nt hoofddorp, nederland.done at brussels, 10.3.2021
 for the commissionsandra gallina
 director-general</p></section></body></xml>